Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-29
2008-07-29
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S398000
Reexamination Certificate
active
07405197
ABSTRACT:
The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG, or a bio-analogue, is administered during the follicular phase.
REFERENCES:
patent: 5705478 (1998-01-01), Boime
patent: 6653286 (2003-11-01), Mannaerts et al.
patent: 0 170 502 (1991-06-01), None
patent: WO-99/13081 (1999-03-01), None
patent: WO-00/50066 (2000-08-01), None
patent: WO-00/67778 (2000-11-01), None
patent: WO-01/54715 (2001-08-01), None
David Lindsay Healy et al, “Female Infertility: Causes and Treatment”, The Lancet, Jun. 18, 1994, vol. 343, pp. 1539-1544.
Marco Filicori, “Gonadotropin-Releasing Hormone Analogs in Ovulation Induction: Current Status and Perspectives”, Journal of Clinical Endocrinology and Metabolism, 1996, vol. 81, pp. 2413-2416.
Marco Filicori et al, “Different Gonadotropin and Leuprotein Ovulation Induction Regimens Markedly Affect Follicular Fluid Hormone Levels and Folliculogenesis”, Fertility and Sterility, Feb. 1996, vol. 65, pp. 387-393.
M. Filicori et al, “Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome”, The Journal of Clinical Endocrinology and Metabolism, 1999, vol. 84, pp. 2659-2663.
Ioannis E. Messinis, M.D. et al, “The Importance of Human Chorionic Gonadotropin Support of the Corpus Luteum During Human Gonadotropin Therapy in Women with Anovulatory Infertility”, Fertility and Sterility, vol. 50, pp. 31-35.
Z.M. Lei et al, “The Expression of Human Chorionic Gonadotropin/Luteinizing Hormone Receptors in Human Endometrial and Myometrial Blood Vessels”, 1992, vol. 75, pp. 651-659.
Hugh P. J. Bennett et al, “Peptide Hormones and Their Analogues: Distribution, Clearance from the Circulation, and Inactivation in Vivo”, Pharmacological Reviews, 1979, vol. 30, pp. 247-292.
B.M.J.L. Mannaerts et al, “A Randomized Three-Way Cross-Over Study in Healthy Pituitary-Suppressed Women to Compare the Bioavailability of Human Chorionic Gonadotropin . . . ”, Human Reproduction, 1998, vol. 13, pp. 1461-1464.
Wiebe Olijve et al, “Molecular Biology and Biochemistry of Human Recombinant Follicle Stimulating Hormone (Puregon)”, Molecular Human Reproduction, 1996, vol. 2, pp. 371-382.
Tadashi Sugahara et al, “Biosynthesis of a Biologically Active Single Peptide Chain Containing the Human Common α and Chorionic Gonadotropin β Subunits in Tandem”, Medical Sciences, 1995, vol. 92, pp. 2041-2045.
Judith L. Vaitukaitis et al, “A Radioimmunoassay Which Specifically Measures Human Chorionic Gonadotropin in the Presence of Human Luteinizing Hormone”, Am. J. Obstet., Gynecol., Jul. 15, 1982, vol. 113, pp. 751-758.
“Radioimmunoassay of Human Choriogonadotropin”, Clinical Chemistry, 1985, col. 31, pp. 1749-1754.
Lee Tyrey, “Human Chorionic Gonadotropin Assays and Their Uses”, Obstetrics and Gynecology Clinics of North America, Sep. 1988, vol. 15, pp. 457-475.
Kimberly A. Thompson et al, “Gonadotropin Requirements of the Developing Follicle”, Fertility and Sterility, 1995, vol. 63, pp. 273-276.
Zeev Blumenfeld et al, “Early Pregnancy Wastage: The Role of Repetitive Human Chorionic Gonadotropin Supplementation During the First 8 Weeks of Gestation”, Fertility and Sterility, Jul. 1992, vol. 58, pp. 19-23.
M. Filicori et al, “Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome”, The Journal of Endocrinology and Metabolism, 1999, vol. 84, pp. 2653-2663.
W.R. Robertson et al, “the In Vitro bioassay of Peptide Hormones”, Peptide Hormones; a Practical Approach, IRL Press, Oxford, 1990, pp. 121-159.
Allen Marianne P.
Browdy and Neimark PLLC
DeBerry Regina M
Laboratories Serono SA
LandOfFree
Use of hCG in controlled ovarian hyperstimulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hCG in controlled ovarian hyperstimulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hCG in controlled ovarian hyperstimulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2794035